These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 27262905)
21. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Thomsen MB; Verduyn SC; Stengl M; Beekman JD; de Pater G; van Opstal J; Volders PG; Vos MA Circulation; 2004 Oct; 110(16):2453-9. PubMed ID: 15477402 [TBL] [Abstract][Full Text] [Related]
22. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics. Calderone V; Testai L; Martinotti E; Del Tacca M; Breschi MC J Pharm Pharmacol; 2005 Feb; 57(2):151-61. PubMed ID: 15720777 [TBL] [Abstract][Full Text] [Related]
23. Analysis of torsadogenic and pharmacokinetic profile of E-4031 in dogs bridging the gap of information between in vitro proarrhythmia assay and clinical observation in human subjects. Goto A; Izumi-Nakaseko H; Hagiwara-Nagasawa M; Chiba K; Ando K; Naito AT; Sugiyama A J Pharmacol Sci; 2018 Jun; 137(2):237-240. PubMed ID: 29980434 [TBL] [Abstract][Full Text] [Related]
24. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254 [TBL] [Abstract][Full Text] [Related]
25. Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Chiba K; Sugiyama A; Satoh Y; Shiina H; Hashimoto K Toxicol Appl Pharmacol; 2000 Nov; 169(1):8-16. PubMed ID: 11076691 [TBL] [Abstract][Full Text] [Related]
26. Risperidone alone did not induce torsade de pointes: Experimental evidence from the chronic atrioventricular block model dogs. Nunoi Y; Chiba K; Hagiwara-Nagasawa M; Goto A; Kambayashi R; Izumi-Nakaseko H; Takei Y; Matsumoto A; Watanabe Y; Sugiyama A J Pharmacol Sci; 2020 Aug; 143(4):330-332. PubMed ID: 32499094 [TBL] [Abstract][Full Text] [Related]
27. Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model. Varkevisser R; van der Heyden MA; Tieland RG; Beekman JD; Vos MA Eur J Pharmacol; 2013 Nov; 720(1-3):49-54. PubMed ID: 24211677 [TBL] [Abstract][Full Text] [Related]
28. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization. Tabo M; Kimura K; Ito S J Pharmacol Toxicol Methods; 2007; 55(3):254-61. PubMed ID: 17229580 [TBL] [Abstract][Full Text] [Related]
29. Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by IKr blockers. Milberg P; Fleischer D; Stypmann J; Osada N; Mönnig G; Engelen MA; Bruch C; Breithardt G; Haverkamp W; Eckardt L Basic Res Cardiol; 2007 Jan; 102(1):42-51. PubMed ID: 16817026 [TBL] [Abstract][Full Text] [Related]
30. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia]. Gury C; Canceil O; Iaria P Encephale; 2000; 26(6):62-72. PubMed ID: 11217540 [TBL] [Abstract][Full Text] [Related]
31. No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block. Thomsen MB; Beekman JD; Attevelt NJ; Takahara A; Sugiyama A; Chiba K; Vos MA Br J Pharmacol; 2006 Dec; 149(8):1039-48. PubMed ID: 17088870 [TBL] [Abstract][Full Text] [Related]
32. Does the sedative agent, JM-1232(-) cause QT prolongation with subsequent torsades de pointes? Kato R; Watanabe R; Miki H; Ijiri Y; Hayashi T; Tanaka K Life Sci; 2009 Nov; 85(21-22):737-41. PubMed ID: 19833140 [TBL] [Abstract][Full Text] [Related]
33. [Torsade de pointes--a cause of Morgagni-Adam-Stokes attacks in patients with complete atrioventricular block]. Antonelli D; Rozner E; Freedberg NA; Turgeman Y Harefuah; 2008 Mar; 147(3):204-6, 279. PubMed ID: 18488859 [TBL] [Abstract][Full Text] [Related]
34. Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. Tei Y; Morita T; Inoue S; Miyata H Psychosomatics; 2004; 45(5):450-1. PubMed ID: 15345794 [No Abstract] [Full Text] [Related]
35. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome. Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388 [TBL] [Abstract][Full Text] [Related]
36. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome. Johansson M; Carlsson L J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331 [TBL] [Abstract][Full Text] [Related]
37. Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. Antoons G; Oros A; Beekman JD; Engelen MA; Houtman MJ; Belardinelli L; Stengl M; Vos MA J Am Coll Cardiol; 2010 Feb; 55(8):801-9. PubMed ID: 20170820 [TBL] [Abstract][Full Text] [Related]
38. QT and TdP. QT: an unreliable predictor of proarrhythmia. Hondeghem LM Acta Cardiol; 2008 Feb; 63(1):1-7. PubMed ID: 18372573 [TBL] [Abstract][Full Text] [Related]
40. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model. Lu HR; Gallacher DJ; Yan GX J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]